Clinical trial · Interventional
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
An Open-label Study of MabThera on Objective Overall Tumor Response in Treatment-naïve Patients With Non-bulky Follicular Non-Hodgkin's Lymphoma
NCT01392716CI-TRIAL-00024657completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin's lymphoma. The anticipated time on study treatment is 3 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| rituximab [MabThera/Rituxan] | Drug | Rituximab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Single arm
- interventionNames
- Drug: rituximab [MabThera/Rituxan]
Primary outcomes (2)
- measure
- Overall objective complete response rate
- timeFrame
- Day 50
- measure
- Overall objective partial response rate
- timeFrame
- Day 50
Secondary outcomes (5)
- measure
- Progression-free survival
- timeFrame
- 7 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients 18-75 years of age * Newly diagnosed non-bulky follicular non-Hodgkin's lymphoma * \>/=1 measurable lesion * No prior treatment (no corticosteroids or radiotherapy) Exclusion Criteria: * Transformed follicular lymphoma * Cerebral or meningeal lymphomaotus localization * Uncontrolled concurrent infection
References
Publications (0)
Data not yet available
No reference posted for this study.